Clinical Trial Update: A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial of subcutaneous tocilizumab (RoActemra/Actemra) as monotherapy or with conventional DMARDs in active rheumatoid arthritis completed; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RoActemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2018-01-26